Dataset opportunity
Elucidbio — 医疗影像数据集机会
Elucidbio 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
42%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2025 年为 18.8 亿美元，复合年增长率为 36.91%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-08
Elucid raises $55M to commercialize cardiovascular imaging platform
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能和诊断影像公司
Elucidbio 提供了一个高价值的医疗影像数据集，其中包括大量的 `image_collection` 和相应的 `medical_records`。该数据集为诊断人工智能应用进行了独特准备，因为它构成了其自身获得 FDA 批准的诊断软件的基础。其核心价值在于专有的、经组织学验证的真实标签，为训练和验证先进的人工智能模型提供了稀有且极其准确的资源。
该数据服务于快速扩张的全球医疗影像人工智能市场，该市场在 2025 年的价值为18.8 亿美元，预计将以 36.91% 的激进复合年增长率增长。[4] 虽然访问需要应对 HIPAA 合规性、临床试验隐私规则以及数据与专有软件的深度集成等复杂性，但其已证实的效用和独特的验证使其成为旨在进入这个高增长市场的买家的宝贵资产。[4] ⚠ 尽职调查（有价值的数据，可协商的访问权限）：医疗数据受 HIPAA 和严格的临床试验隐私法规约束；数据与他们的 FDA 批准的诊断软件深度集成；专有的经组织学验证的真实标签是他们的主要竞争优势。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据证实 Elucidbio 拥有一项专有的、大规模的医疗影像数据集，该数据集已针对组织学（心血管斑块的临床金标准）进行了独特验证。该集合对于希望构建和验证下一代诊断人工智能以无创方式识别高风险病症的医疗人工智能公司至关重要。在一个预计到 2025 年将达到 18.8 亿美元的市场中，该数据集提供了训练算法识别特定高风险斑块特征（如富含脂质的坏死核心）所需的真实标签。获取这些数据通过加速开发高度准确的无创诊断工具，提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“医疗记录”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume46
2 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于医疗影像人工智能市场的爆炸式增长，该市场正以 36.91% 的复合年增长率扩张。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength50
2 种证据类型，2 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ 审查 — Elucid 的核心业务是销售获得 FDA 批准的 AI 软件，该软件分析医疗影像以提供情报，这使其成为一个糟糕的目标，因为它已经是市场上的供应商。问题：公司的核心产品是销售情报/AI 软件（PlaqueIQ™）来分析 CTA 扫描，而不是作为副产品生成数据。[4, 6, 8]；公司的商业模式基于其分析平台的软件许可和订阅。[4]；该公司被定义为“医疗技术公司”或“面向提供商的基于 AI 的动脉分析软件”，而不是主要数据持有者。[1, 2, 9]
- Deep Qualification90
✓ 通过 — Elucid 是一家工具供应商，销售用于心血管影像分析的 FDA 批准的 AI 软件；虽然它拥有独特的经组织学验证的训练数据集，但其客户生成的数据仍归客户所有，这造成了显著的访问和所有权复杂性。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Image collection
持有者拥有独特的图像集合，已通过组织学（临床金标准）进行了验证，为训练高精度诊断模型提供了无与伦比的真实标签。
Medical records / imaging
这些证据表明存在一个用于训练专有算法的大规模注释组织样本数据集，这对于开发能够自动检测高风险斑块特征的人工智能至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Elucidbio Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = $1.88 billion in 2025, CAGR 36.91% (source: Fortune Business Insights). [4]. Investment score 45.0/100 (confidence 0.42). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Nrstor — 工业传感器数据集机会
View opportunity →工业Solup — 检验报告数据集机会
View opportunity →工业Caliber — 维护日志数据集机会
View opportunity →